Skip to main content Accessibility help
×
Home

Invited commentary on: Cost-effectiveness of current and optimal treatment for schizophrenia

  • David Goldberg (a1)
  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Invited commentary on: Cost-effectiveness of current and optimal treatment for schizophrenia
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Invited commentary on: Cost-effectiveness of current and optimal treatment for schizophrenia
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Invited commentary on: Cost-effectiveness of current and optimal treatment for schizophrenia
      Available formats
      ×

Abstract

Copyright

References

Hide All
Andrews, G., Sanderson, K., Corry, J., et al (2003) Cost-effectiveness of current and optimal treatment for schizophrenia. British Journal of Psychiatry, 183, 427435.
Czernansky, J. G., Mahmoud, R., Brenner, R. (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine, 346, 1622.
Jones, R., Goldberg, D. P. & Hughes, B. (1981) A comparison of two different services treating schizophrenia: a cost–benefit approach. Psychological Medicine, 10, 493505.
Rosenheck, R., Cramer, J., Allan, E., et al (1999) Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Archives of General Psychiatry, 56, 565572.
Sernyak, M. J., Rosenheck, R., Desai, R., et al (2001) Impact of clozapine prescription on inpatient resource utilization. Journal of Nervous and Mental Disease, 189, 766773.
Thornicroft, G., Wykes, T., Holloway, F., et al (1998) From efficacy to effectiveness in community mental health services. PRiSM Psychosis Study 10. British Journal of Psychiatry, 173, 423427.
World Health Organization (2001) Atlas: Country Profiles on Mental Health Resources. Geneva: WHO.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Invited commentary on: Cost-effectiveness of current and optimal treatment for schizophrenia

  • David Goldberg (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *